001     289652
005     20250328112418.0
024 7 _ |a 10.1186/s13008-024-00116-y
|2 doi
024 7 _ |a pmid:38643120
|2 pmid
024 7 _ |a pmc:PMC11031927
|2 pmc
024 7 _ |a altmetric:162707387
|2 altmetric
037 _ _ |a DKFZ-2024-00834
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Pagliari, Francesca
|0 P:(DE-He78)d06e5bb2d0828caa2be79a51825e84e1
|b 0
|e First author
|u dkfz
245 _ _ |a Cancer radioresistance is characterized by a differential lipid droplet content along the cell cycle.
260 _ _ |a London
|c 2024
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1713773265_20489
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:E041#LA:E041#
520 _ _ |a Cancer radiation treatments have seen substantial advancements, yet the biomolecular mechanisms underlying cancer cell radioresistance continue to elude full understanding. The effectiveness of radiation on cancer is hindered by various factors, such as oxygen concentrations within tumors, cells' ability to repair DNA damage and metabolic changes. Moreover, the initial and radiation-induced cell cycle profiles can significantly influence radiotherapy responses as radiation sensitivity fluctuates across different cell cycle stages. Given this evidence and our prior studies establishing a correlation between cancer radiation resistance and an increased number of cytoplasmic Lipid Droplets (LDs), we investigated if LD accumulation was modulated along the cell cycle and if this correlated with differential radioresistance in lung and bladder cell lines.Our findings identified the S phase as the most radioresistant cell cycle phase being characterized by an increase in LDs. Analysis of the expression of perilipin genes (a family of proteins involved in the LD structure and functions) throughout the cell cycle also uncovered a unique gene cell cycle pattern.In summary, although these results require further molecular studies about the mechanisms of radioresistance, the findings presented here are the first evidence that LD accumulation could participate in cancer cells' ability to better survive X-Ray radiation when cells are in the S phase. LDs can represent new players in the radioresistance processes associated with cancer metabolism. This could open new therapeutic avenues in which the use of LD-interfering drugs might enhance cancer sensitivity to radiation.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Cancer metabolism
|2 Other
650 _ 7 |a Cell cycle
|2 Other
650 _ 7 |a Lipid droplets
|2 Other
650 _ 7 |a Perilipins
|2 Other
650 _ 7 |a Radioresistance
|2 Other
700 1 _ |a Jansen, Jeannette
|0 P:(DE-He78)02e29e2d540ff21d777f3a03ec9f5ade
|b 1
|e First author
700 1 _ |a Knoll, Jan
|0 P:(DE-He78)483e25de20b0e09c44b46bdbdd7036c2
|b 2
700 1 _ |a Hanley, Rachel
|0 P:(DE-He78)15d0e694db442a1762a025b802a56f75
|b 3
700 1 _ |a Seco, Joao
|0 P:(DE-He78)102624aca75cfe987c05343d5fdcf2fe
|b 4
|e Last author
|u dkfz
700 1 _ |a Tirinato, Luca
|0 P:(DE-He78)62f71d68e658453766d3f349b2b718d4
|b 5
|e Last author
773 _ _ |a 10.1186/s13008-024-00116-y
|g Vol. 19, no. 1, p. 14
|0 PERI:(DE-600)2236097-9
|n 1
|p 14
|t Cell division
|v 19
|y 2024
|x 1747-1028
856 4 _ |u https://inrepo02.dkfz.de/record/289652/files/s13008-024-00116-y.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/289652/files/s13008-024-00116-y.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:289652
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)d06e5bb2d0828caa2be79a51825e84e1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)02e29e2d540ff21d777f3a03ec9f5ade
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)483e25de20b0e09c44b46bdbdd7036c2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)15d0e694db442a1762a025b802a56f75
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)102624aca75cfe987c05343d5fdcf2fe
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)62f71d68e658453766d3f349b2b718d4
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL DIV : 2022
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T09:07:18Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T09:07:18Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-05-02T09:07:18Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-19
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-19
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-19
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-19
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-19
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a Local Funding
|2 APC
|0 PC:(DE-HGF)0001
915 p c |a DFG OA Publikationskosten
|2 APC
|0 PC:(DE-HGF)0002
915 p c |a DOAJ Journal
|2 APC
|0 PC:(DE-HGF)0003
920 2 _ |0 I:(DE-He78)E041-20160331
|k E041
|l Med. Physik in der Radioonkologie
|x 0
920 1 _ |0 I:(DE-He78)E041-20160331
|k E041
|l Med. Physik in der Radioonkologie
|x 0
920 0 _ |0 I:(DE-He78)E041-20160331
|k E041
|l Med. Physik in der Radioonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E041-20160331
980 _ _ |a UNRESTRICTED
980 _ _ |a APC


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21